Search the RE article base
Contact Information
Twitter
My TweetsUseful Web Sites
Category Archives: high priced drugs
March-in rights, Xtandi, and Bayh-Dole’s patent rights clause
Senator Bernie Sanders just tweeted about Xtandi, asking patients taking Xtandi to share their stories. The prostate cancer drug Xtandi was invented by taxpayer-funded scientists at UCLA, but now costs Americans nearly $190,000 — or up to six times the … Continue reading
Posted in Bayh-Dole, high priced drugs
Tagged Bayh-Dole, competition, march-in, reasonable terms, Xtandi
Comments Off on March-in rights, Xtandi, and Bayh-Dole’s patent rights clause
Bayh-Dole on 200 drugs, 3
We are working through examples of the claim that Bayh-Dole has led to the creation of 200 new drugs. There’s been a lot of post hoc fallaciphizing–that because Bayh-Dole came before some of these new drugs, they must have come … Continue reading
Posted in Bayh-Dole, high priced drugs, Technology Transfer
Tagged 200, Bayh-Dole, drug
Comments Off on Bayh-Dole on 200 drugs, 3
Bayh-Dole on 200 drugs, 2
We are working through claims that Bayh-Dole has produced 200 new drugs where before there was nothing, nothing, nothing at all. In back of it all are three key points: Bayh-Dole means nothing if federal contractors and agencies license non-exclusively. … Continue reading
Posted in Bayh-Dole, high priced drugs
Tagged 200, Bayh-Dole, drug
Comments Off on Bayh-Dole on 200 drugs, 2
Bayh-Dole march-in won’t change drug prices but other things might–2
Now let’s look at alternatives to Bayh-Dole’s march-in procedures to address competition, public access, and prevention of unreasonable use, including price gouging. We will consider two within Bayh-Dole and two outside Bayh-Dole. The Bayh-Dole alternatives are: use the government license … Continue reading
Posted in Bayh-Dole, high priced drugs, Policy
Tagged assignment, Bayh-Dole, license, patent law, reasonable compensation
Comments Off on Bayh-Dole march-in won’t change drug prices but other things might–2
Bayh-Dole march-in won’t change drug prices but other things might–1
Folks think that somehow Bayh-Dole permits government take over of pharma patents and by doing this, somehow, the price of drugs will necessarily–magically–go down. Let’s work through this idea. Set aside for a moment that many drugs don’t do much … Continue reading
Posted in Bayh-Dole, high priced drugs, Policy
Tagged assignment, Bayh-Dole, drugs, license, price
Comments Off on Bayh-Dole march-in won’t change drug prices but other things might–1
Bayh-Dole government-wide licenses
In a Twitter thread in which Jennifer Gunter argues that “Americans should not be bankrolling the pharmaceutical industry,” Steven Martin tweets Let’s work this through. There is no need to revise Bayh-Dole for state and municipal governments to authorize the … Continue reading
Posted in Bayh-Dole, high priced drugs
Tagged Bayh-Dole, government license, government-wide license, nonprofit patent rights clause
Comments Off on Bayh-Dole government-wide licenses